Synthetic STxB-based mucosal vaccination platform
Scale or prepare manufacturing, process control, GMP readiness and quality workflows.
Offer overview
What this offer helps you achieve
Scale or prepare manufacturing, process control, GMP readiness and quality workflows.
Scientific and technical scope
Our platform leverages chemical synthesis for efficient mucosal vaccination. Unlike mRNA vaccines, our synthetic STxB induces robust CD8+ T cell responses and mucosal IgA and IgG, crucial for preventing viral spread. This innovation is advancing in preclinical stages, with ongoing COVID-19 and Head & Neck carcinoma model studies demonstrating promising in vitro and in vivo proof of concept.
Capabilities mobilised
Therapeutic areasFormulation and synthesisValidation using preclinical modelsBioproduction
Application fields
Oncology
Discuss this offer
Could this capability strengthen your R&D programme?
Present your scientific, technical or clinical need and identify the most relevant route to collaboration.
Continue exploring
Related expertise for your programme
Offers selected through shared capabilities, application fields or institute expertise.
